STOCK TITAN

Medicus Pharma Ltd. Warrant (MDCXW) Stock Price, News & Analysis

MDCXW NASDAQ
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
85 149 sessions, November 14, 2025 to November 16, 2026
Largest daily move
+148.2% close of April 28, 2026
1-year change
-79.6% closing prices, November 14, 2025 to November 16, 2026
1-month change
-23.1% closing prices, October 16, 2026 to November 16, 2026

Company Description

Medicus Pharma Ltd. (trading under the symbol MDCXW) is described in available public information as a clinical-stage holding company in the life sciences and biotechnology space. According to third-party data, the company focuses on investing in and accelerating novel life sciences and biotechnology businesses through clinical development governed by U.S. Food and Drug Administration (FDA) requirements, with an emphasis on improving patient safety and treatment efficacy.

Medicus Pharma Ltd. is incorporated under the laws of the Province of Ontario, Canada. Its sector classification is in pharmaceutical preparations, indicating a focus on therapies and technologies related to medical treatment and drug development. The company’s structure as a holding company suggests that its activities are organized around owning and supporting operating subsidiaries or assets in the life sciences and biotechnology fields, rather than directly conducting all clinical operations itself.

Corporate structure and jurisdiction

Public filings state that Medicus Pharma Ltd. is an Ontario, Canada corporation. This legal structure places the company under Canadian corporate law, while its activities and financing arrangements may extend into other jurisdictions through its subsidiaries and financing partners. The company references subsidiaries that provide guarantees in connection with certain financing arrangements, which indicates a group structure where multiple entities support the obligations of the parent company.

Focus on clinical-stage life sciences and biotechnology

Available descriptions characterize Medicus Pharma Ltd. as a clinical-stage holding company. In this context, "clinical-stage" refers to a focus on products, technologies, or portfolio companies that are in human clinical testing regulated by the FDA. The company’s stated aim is to help advance novel life sciences and biotechnology assets through FDA-approved clinical trials, with an explicit focus on addressing unmet medical needs and improving patient safety and efficacy.

Rather than being described as a commercial-stage pharmaceutical manufacturer, Medicus Pharma Ltd. is presented as concentrating on the development and advancement phase of life sciences and biotechnology assets. This includes supporting clinical programs that must meet regulatory standards for safety and effectiveness before potential broader medical use.

Financing and capital structure considerations

In a Form 8-K filed with the U.S. Securities and Exchange Commission, Medicus Pharma Ltd. reported entering into a securities purchase agreement involving the issuance of a debenture to an institutional investor. The filing describes a debenture with a stated principal amount, interest terms, a maturity date, and a schedule of monthly installment payments. The company also disclosed that the net proceeds from this debenture were used in part to satisfy an existing outstanding balance from prior debentures, with the remainder affected by original issue discount and related fees and expenses.

The same filing explains that, at the time of this financing, each of the company’s subsidiaries entered into a global guaranty agreement in favor of the investor, guaranteeing the company’s obligations under the purchase agreement and the debenture. This indicates that Medicus Pharma Ltd. uses secured financing arrangements that involve obligations at both the parent and subsidiary levels, and that its capital structure includes interest-bearing debt instruments documented in SEC filings.

Regulatory reporting and exchange information

Medicus Pharma Ltd. files reports with the U.S. Securities and Exchange Commission under a commission file number that identifies it as a registrant. The Form 8-K describing the debenture transaction notes that the company’s securities are associated with an exchange designation, reflecting that its securities are listed or quoted in a U.S. market context. Through these filings, investors and observers can review material definitive agreements, direct financial obligations, and other events that the company determines to be significant.

As a company in the pharmaceutical preparations sector and life sciences and biotechnology space, Medicus Pharma Ltd.’s regulatory disclosures provide insight into its financing activities and corporate structure, even when detailed information about specific clinical programs or portfolio companies is not included in the available summary descriptions.

Business purpose and strategic emphasis

Medicus Pharma Ltd. focuses on investing in and accelerating novel life sciences and biotechnology companies through the clinical development process. The stated emphasis is on meeting unmet needs in patient care, with a particular focus on safety and efficacy. This suggests that the company’s role is to support the advancement of medical technologies or therapies that seek to improve clinical outcomes and address gaps in existing treatment options.

Because the company is described as a holding company, its business purpose centers on owning and supporting interests in underlying life sciences and biotechnology assets rather than directly marketing finished pharmaceutical products. The emphasis on FDA-approved clinical trials highlights the importance of regulatory pathways and clinical evidence in the company’s activities.

Use of SEC disclosures by investors

Investors and analysts who follow Medicus Pharma Ltd. can use its SEC filings to understand key aspects of its operations and financial obligations. The Form 8-K describing the securities purchase agreement and debenture outlines the terms under which the company raises capital, including interest rates, maturity, repayment schedules, and optional redemption rights. It also identifies the role of subsidiaries in guaranteeing these obligations.

These disclosures help provide transparency into how Medicus Pharma Ltd. finances its clinical-stage and holding company activities, how it manages existing debt, and how it structures agreements with institutional investors. For a company in the life sciences and biotechnology sector, such financing arrangements can be an important part of supporting ongoing clinical development and related corporate objectives.

Stock Performance

$0.2000
+0.00%
+0.0000
Last updated: at
-79.6%
Performance 1 year

Medicus Pharma Ltd. Warrant (MDCXW) closed at $0.2000 on November 16, 2026. Over the past 12 months, the price has lost 79.6%.

See what a $1,000 investment in MDCXW would be worth today

Average down calculator for MDCXW

MDCXW Metrics & Rankings

Price returns through November 16, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

No recent news available for MDCXW.

Financial Highlights

Medicus Pharma Ltd. Warrant reported operating income of -$34.4M in FY2025, and net income was -$47.3M. Diluted earnings per share stood at -$137.00. The company generated -$22.8M in operating cash flow. The current ratio was 1.00, measuring current assets divided by current liabilities.

-$47.3M
Net Income (FY2025)
-$22.8M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

No upcoming events scheduled for MDCXW.

Short Interest History

Last 12 Months

Short interest in Medicus Pharma Ltd. Warrant (MDCXW) currently stands at 16.3 thousand shares, down 29.4% from the previous reporting period. Since November 2025, short interest has decreased by 45.6%.

Days to Cover History

Last 12 Months

Days to cover for Medicus Pharma Ltd. Warrant (MDCXW) currently stands at 21.4 days, down 23.4% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 50.8%. Across the settlements charted above, it has ranged from 2.8 to 558.9 days.

MDCXW Company Profile & Sector Positioning

Medicus Pharma Ltd. Warrant (MDCXW) and is listed on the NASDAQ.

Investors comparing MDCXW often look at related companies in the same sector, including Alkermes Inc. plc (ALKS), Acadian Asset Management Inc. (AAMI), Horizon Bancorp, Inc. (HBNC), Rafael Holdings, Inc. (RFL), and Curanex Pharmaceuticals Inc (CURX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate MDCXW's relative position within its industry.

Frequently Asked Questions

The current stock price of Medicus Pharma Ltd. Warrant (MDCXW) is $0.2000 as of November 16, 2026.

The FY2025 net income of Medicus Pharma Ltd. Warrant (MDCXW) is -$47.3M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Medicus Pharma Ltd. Warrant (MDCXW) is -$137.00 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Medicus Pharma Ltd. Warrant (MDCXW) is -$22.8M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Medicus Pharma Ltd. Warrant (MDCXW), current assets divided by current liabilities, was 1.00 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Medicus Pharma Ltd. Warrant (MDCXW) is -$34.4M for FY2025, its most recent completed fiscal year. Learn about operating income.

Medicus Pharma Ltd. is described as a clinical-stage holding company focused on investing in and accelerating novel life sciences and biotechnology companies. Its activities center on advancing assets through FDA-governed clinical trials with an emphasis on improving patient safety and treatment efficacy.

Public information indicates that Medicus Pharma Ltd. is incorporated under the laws of the Province of Ontario, Canada and operates as a holding company. SEC filings reference subsidiaries that provide guarantees in connection with the company’s financing arrangements, suggesting a group structure with multiple affiliated entities.

Medicus Pharma Ltd. is classified in the pharmaceutical preparations sector, with a focus on life sciences and biotechnology. Its clinical-stage orientation reflects involvement with assets undergoing FDA-regulated clinical development.

Medicus Pharma Ltd. focuses on assets that are in human clinical testing under FDA oversight. As a holding company, it supports and owns interests in life sciences and biotechnology businesses rather than directly marketing finished pharmaceutical products.

Medicus Pharma Ltd. aims to meet unmet medical needs by improving patient safety and efficacy. This focus is linked to its role in advancing novel life sciences and biotechnology assets through FDA-approved clinical trials.

In a Form 8-K, Medicus Pharma Ltd. reported entering into a securities purchase agreement with an institutional investor for the issuance of a debenture. The filing describes the debenture’s principal amount, interest terms, maturity date, and monthly installment payments, as well as the use of proceeds to satisfy an existing debenture balance and cover discounts and fees.

The Form 8-K states that, in connection with the securities purchase agreement and debenture, each of Medicus Pharma Ltd.’s subsidiaries entered into a global guaranty agreement in favor of the investor. These guarantees back the company’s obligations under the purchase agreement and the debenture.

Investors can review Medicus Pharma Ltd.’s filings with the U.S. Securities and Exchange Commission, including Form 8-K reports that describe material definitive agreements, direct financial obligations, and other significant events. These filings provide details on the company’s capital structure and certain aspects of its operations.